Drugs / scAAV9/JeT-GAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07543991 | Mar 2026 → Dec 2031 expected | giant axonal neuropathy | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAV9/JeT-GAN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07543991 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy containing the GAN transgene)” PMID 38507752 ↗ Mar 2024 |
| Route | Other | “a single injection of scAAV9/JeT-GAN, given directly into the left vagus nerve” NCT07543991 ↗ |